Serum FST levels were significantly increased in Flt3/ITD knock‐in mouse and FLT3/ITD AML patient‐derived xenografted mice and were correlated with clinical responses to quizartinib in AML patients. Here, FLT3 is linked to acute myeloid leukemia.